GI-5005 + peginterferon alfa + ribavirin

GI-5005 + peginterferon alfa + ribavirin is a combination therapy formerly investigated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. The regimen consists of GI-5005, a Tarmogen therapeutic vaccine comprising heat-inactivated recombinant Saccharomyces cerevisiae yeast expressing a fusion of HCV NS3 and Core proteins, administered alongside the standard of care (SOC) components peginterferon alfa and ribavirin. GI-5005 was designed to stimulate an HCV-specific T-cell immune response to reduce the viral load in infected cells. Despite showing immunogenicity and some improvements in ALT levels in Phase 2 trials, the triple combination failed to significantly improve sustained virologic response (SVR) rates compared to SOC alone in treatment-naive patients or those who had previously failed therapy. Consequently, GlobeImmune discontinued the development of GI-5005 for HCV.

Other names

GI-5005 + pegylated interferon + ribavirinGI-5005 + SOC